ClinicalTrials.gg
Active, not recruitingNCT06622109Updated Nov 5, 2026

A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months

An observational study in Pneumococcal Disease, sponsored by Pfizer. Active, not recruiting at 1 site in Japan. Open to participants aged 2 Months to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pfizer · Observational

Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,100
Ages
2 Months to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 75 studies in Pneumococcal Infections by Pfizer — 4 open to participants now, 8 under way, 5 of them phase 3. Pneumococcal Infections · Pfizer.

Enrollment
9th of 18
1,100 · median 1,050
Started
2024
with 2 others
Observational
18 of 75
none open now
Registered
68th of 75
by date

Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 9th largest by enrollment of the 18 observational ones that give a count, is one of 3 that started in 2024, is one of 18 observational ones, and was the 68th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

4 of the 75 studies in Pneumococcal Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 2 Months to 6 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Pneumococcal Infections by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety of 20-valent Pneumococcal Conjugate Vaccine (PREVENAR 20) under actual clinical practice in Japan.

This study is seeking for infants aged between two months to six months who are vaccinated with PREVENAR 20 for the first time.

Infants aged between two months and six months are normally given four vaccinations. The first three vaccinations are called primary vaccinations and are given with an interval of one month between each vaccination. The fourth vaccination is called the booster and is given between 12 and 15 months of age.

Participants will take part in this study from the day of first vaccination to 28 days after fourth vaccination.

The side effects observed in the participants will be recorded and looked into.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
2 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Infants aged 2 months, inclusive, to 7 months, exclusive who PREVENAR 20 for the first time.

Eligibility criteria

Inclusion Criteria:

  1. Infants aged 2 months, inclusive, to 7 months, exclusive
  2. Those without a history of pneumococcal vaccination including PREVENAR 20
  3. Those who are expected to receive 4 doses
  4. Those whose parent or legal guardian understands the details of the study and provides consent to provision of information collected in the study to third parties and use of the information for other purposes.

Exclusion Criteria:There are no exclusion criteria for this study.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,100 participants (actual)
Patient registry
No

Groups and cohorts

  • 20-valent Pneumococcal Conjugate Vaccine

    Infants aged 2 months, inclusive to 7 months, exclusive who have been vaccinated with PREVENAR 20 for the first time.

    Biological: 20-valent Pneumococcal Conjugate Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Adverse Reactions(ADRs)

    Time frame: From the first day of each vaccination (1st-4th) up to 28 days after each vaccination (1st-4th).

  2. Percentage of Participants Reporting Serious Adverse Reactions (SADRs)

    Time frame: From the first day of 1st vaccination up to 28 days after 4th vaccination.

07

Study locations

1 site
  • Pfizer
    Tokyo, 151-8589, Japan
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2024
First posted
Oct 1, 2024
StartActual
Nov 25, 2024
Primary completionEst.
Dec 4, 2026
CompletionEst.
Dec 4, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 15, 2026→Dec 4, 2026
Nov 5, 2026
Study completion
Dec 15, 2026→Dec 4, 2026
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Dec 15, 2026→Dec 4, 2026
    Study completion Dec 15, 2026→Dec 4, 2026
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06622109
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Nov 25, 2024
Primary completion
Dec 4, 2026 (estimated)
Completion
Dec 4, 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion